Welcome to our dedicated page for Q/C Technologies SEC filings (Ticker: QCLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Q/C Technologies, Inc. (QCLS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents give detailed insight into how Q/C describes its quantum-class, high-performance computing infrastructure business, its licensing agreement with LightSolver for quantum-inspired laser-based processing units, and its focus on applications in the crypto and blockchain domain.
Through Q/C’s Forms 10-K and 10-Q (when filed), investors can review management’s discussion of operations, risk factors, and financial statements related to its quantum-class photonic computing initiatives and related activities. The company’s Current Reports on Form 8-K disclose material events such as private placements of preferred stock and warrants, amendments to transaction documents, consulting agreements, equity incentive plan changes, and stockholder approvals for reverse stock split authorization and share issuance proposals.
Proxy statements on Schedule 14A outline matters submitted to stockholders, including proposals tied to the issuance of common stock underlying preferred stock and warrants, increases in shares available under the 2021 Equity Incentive Plan, and other governance items. Filings such as Form 12b-25 (Notification of Late Filing) explain any reported delays in submitting periodic reports and the company’s stated plans to file within allowed extension periods.
On Stock Titan, these filings are supplemented with AI-powered summaries that aim to clarify key points from lengthy documents, such as the implications of preferred stock terms, voting rights, equity plan amendments, and reverse stock split proposals. Users can also monitor ownership and compensation-related disclosures contained in proxy materials and other filings, as well as any reported unregistered sales of equity securities and warrant issuances. Real-time updates from EDGAR combined with AI explanations help readers navigate Q/C Technologies’ regulatory history and understand the structural aspects of its quantum-class computing business as presented in its official filings.
Q/C Technologies, Inc. (formerly TNF Pharmaceuticals, Inc.) filed a Form 12b-25 notifying the SEC it cannot timely file its Annual Report on Form 10-K for the year ended December 31, 2025 because it needs additional time to complete and finalize the required financial statements. The company states it currently anticipates filing the Form 10-K on or before the fifteenth calendar day following the prescribed due date. The notice is signed by Joshua Silverman, Executive Chairman, dated March 31, 2026.
Q/C Technologies, Inc. reported that its Audit Committee dismissed Stephano Slack LLC as its independent registered public accounting firm on March 9, 2026, and appointed Grassi & Co., CPAs, P.C. as the new auditor for the year ended December 31, 2025.
The prior auditor’s reports for 2023 and 2024 contained a going concern paragraph noting net loss and negative operating cash flows for 2024 that raised substantial doubt about the Company’s ability to continue as a going concern, with no related adjustments recorded. The Company states there were no disagreements or reportable events with Stephano Slack, and it has obtained a letter from the former auditor addressed to the SEC agreeing with these disclosures.
Q/C Technologies, Inc. has filed a shelf registration statement on Form S-3 to offer and sell, from time to time, up to $100,000,000 of common stock, preferred stock, debt securities, warrants, subscription rights, and units.
The company has shifted its strategy from developing Isomyosamine and Supera-CBD therapeutics to building energy‑efficient blockchain and cryptocurrency infrastructure using laser-based computing under an exclusive global license with LightSolver. The filing notes going concern risks, potential future equity dilution, Nasdaq listing compliance risks, and a high level of investment risk.
Q/C Technologies director Chelsea Sierra Voss reported new equity awards. On January 16, 2026, she received 212,500 shares of common stock as restricted stock units under a consulting agreement and 25,000 additional RSU shares tied to her appointment to the board. Both RSU grants vest in four equal quarterly installments if she continues providing services.
She also received an employee stock option for 212,500 shares of common stock at an exercise price of $5.097 per share, vesting quarterly on the same schedule. Following these awards, she beneficially owns 239,900 shares of common stock directly and 59,802 shares indirectly through a Roth IRA, plus 212,500 stock options.
Q/C Technologies, Inc. director Chelsea Sierra Voss reported her initial ownership of the company’s common stock as of 01/16/2026. She beneficially owns 59,802 shares held indirectly through a Roth IRA and 2,400 shares held directly in her own name.
Q/C Technologies, Inc. entered into a 12‑month consulting agreement with Chelsea Voss on January 16, 2026. She will provide services such as evaluating companies, analyzing technologies and operations, advising on potential acquisitions, and other consulting support requested by the company.
As compensation, Q/C Technologies will pay Ms. Voss $12,500 per month (or $150,000 annually) and grant her 212,500 restricted stock units that vest in four substantially equal quarterly installments, as well as stock options for up to 212,500 shares of common stock with an exercise price per share equal to the greater of $5.097 or the fair market value on the grant date, also vesting quarterly over the term.
The company also appointed Ms. Voss to its board of directors, highlighting her background in large‑scale machine learning and AI systems, including work on GPT‑4, ChatGPT, DALL·E 2, and Codex, and prior software engineering roles at several technology companies.
Q/C Technologies, Inc. (QCLS) reports Q3 2025 results showing a smaller net loss while reshaping its business. For the nine months ended September 30, 2025, the company recorded a net loss of $5,732,326, compared with $21,295,080 a year earlier. After preferred dividends of $2,691,767, the loss attributable to common stockholders was $8,424,093.
Total assets rose to $37,231,786 from $21,421,084, driven by a $14,086,999 technology license and $10,498,539 of goodwill, reflecting its shift toward energy-efficient blockchain and quantum-class laser-based computing. Cash increased to $6,904,185, and marketable securities were $3,091,772 as of September 30, 2025.
The capital structure is complex, with multiple preferred stock series. Mezzanine equity totaled $6,997,894, stockholders’ equity was $14,320,390, and there were 2,977,672 common shares outstanding at September 30, 2025 and 4,166,760 as of November 17, 2025. The company closed the acquisition of LPU Holdings LLC and is executing an exclusive licensing agreement with LightSolver Ltd. to deploy its qc-LPU100™ computing units.
PharmaCyte Biotech, Inc., as a reporting person and 10% owner of Q/C Technologies, Inc. (QCLS), reported derivative equity transactions on a Form 4. On 09/04/2025, the reporting person acquired 889,865 shares of Series H Convertible Preferred Stock and related warrants, each ultimately linked to 889,865 shares of common stock. The Series H preferred is convertible into common stock at a conversion price of $3.3713 per share, subject to adjustment, and its conversion rights do not expire. Both the Series H preferred and the warrants became convertible only after shareholders approved the issuance of the underlying common stock at a special meeting held on November 14, 2025, with the warrants expiring on November 14, 2030.
Q/C Technologies, Inc. (QCLS) reported an equity award to one of its insiders. On 11/14/2025, a director and Chief Medical Officer acquired 11,420 shares of common stock through a grant of restricted stock units at a price of $0 per share, bringing their directly held beneficial ownership to 12,500 shares. The RSUs were originally granted on 10/03/2025, subject to stockholder approval of an amendment to the company’s 2021 Equity Incentive Plan. Stockholders approved this plan amendment on 11/14/2025, and the RSUs vested immediately upon issuance.
Q/C Technologies, Inc. (QCLS) reported an equity award to a director. A board member received 22,839 shares of common stock on November 14, 2025, reported as acquired at a price of $0, bringing this person’s directly held stake to 25,024 shares after the transaction. The shares represent restricted stock units that were originally granted on October 3, 2025 under the company’s 2021 Equity Incentive Plan, subject to stockholder approval of a plan amendment. Stockholders approved that amendment on November 14, 2025, and the RSUs vested immediately upon issuance.